Molecular Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018 Exclusive: Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable'.
After the last spike MBRX stock hit by offering and stock price lost most of the gain that got from the last move last month is this mean it is the end of the story for this stock the answer is not for sure.
Out rate for this stock Buy/Hold Good entry might be between 1.68 up to 1.81 The price target for the next 30 days is 2.50 $.
AKARI THERAPEUTICS PLC SPONSORED ADR AKTX: NASDAQ : the next possible big surprise for March madness if you interested to get all of our update about AKTX and other picks please join our mail list to provide you with details .
Important note : We are just a small team of independent traders and uncertified technical chart analysis and we do not have any insider trading or connection at any of these stocks, you own your decision to buy, hold or sell any of these stocks.
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!